Form 8-K

8-K — AIM ImmunoTech Inc.

Accession: 0001493152-26-016179

Filed: 2026-04-10

Period: 2026-04-10

CIK: 0000946644

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-3.1 (ex3-1.htm)

EX-5.1 (ex5-1.htm)

GRAPHIC (ex5-1_001.jpg)

GRAPHIC (ex5-1_002.jpg)

GRAPHIC (ex5-1_003.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0000946644

2026-04-10

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 OR 15(d) of The

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): April 10, 2026

AIM

IMMUNOTECH INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-27072

52-0845822

(state

or other jurisdiction

(Commission

(IRS

Employer

incorporation)

File

Number)

Identification

No.)

2117

SW Highway 484, Ocala, FL

34473

(Address

of principal executive offices)

(Zip

Code)

Registrant’s

telephone number, including area code: (352) 448-7797

(Former

name or former address, if changed since last report.)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions (see General Instruction A.2. below):

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate

by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933

(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities

registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol

Name

of each exchange on which registered

Common

Stock, par value $0.001 per share

AIM

NYSE

American

Item

1.01 Entry into a Material Definitive Agreement.

April 10, 2026, AIM ImmunoTech Inc. (the “Company”) entered into Amendment No. 1 (the “Amendment”) to that certain

Equity Distribution Agreement dated April 1, 2025 (the “Sales Agreement”) with Maxim Group LLC (“Maxim”) to act

as the Company’s exclusive sales agent with respect to the issuance and sale of up to $3,000,000 of the Company’s shares

of common stock, par value $0.001 per share (the “Shares”), from time to time, in an at-the-market public offering (the “Offering”).

The Amendment removes the limitation of the amount of Shares to be sold under the Sales Agreement.

The

Shares will be sold and issued pursuant the Company’s shelf registration statement on Form S-3 (File No. 333-286319), which was

previously declared effective by the Securities and Exchange Commission, and a related prospectus, as supplemented. The Company is simultaneously

herewith filing a supplement to the prospectus supplement with the Securities and Exchange Commission to increase the number of Shares

that may be offered and sold in the Offering.

Item

9.01 Financial Statements and Exhibits.

Exhibit

No.

Description

3.1

Amendment to Equity Distribution Agreement dated April 10, 2026

5.1

Opinion of Thompson Hine LLP

23.1

Consent of Thompson Hine LLP (included in the opinion filed as Exhibit 5.1)

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

AIM

ImmunoTech Inc.

Dated:

April 10, 2026

/s/

Thomas K. Equels

Thomas

K. Equels, CEO

EX-3.1

Filename: ex3-1.htm · Sequence: 2

Exhibit

3.1

FIRST

AMENDMENT TO

EQUITY

DISTRIBUTION agreement

This

FIRST AMENDMENT TO EQUITY DISTRIBUTION AGREEMENT (this “Amendment”) is entered into as of April 10, 2026, by and between

AIM ImmunoTech Inc., a Delaware corporation (the “Company”), and Maxim Group LLC (the “Agent”).

WHEREAS,

the Company and the Agent entered into an Equity Distribution Agreement, dated April 1, 2025 (the “Agreement”), pursuant

to which the Company may issue and sell, through the Agent, its shares of common stock;

WHEREAS,

the Agreement provides that the Company may cause the Agent to sell common stock of the Company having an aggregate offering price of

up to $3.0 million; and

WHEREAS,

the Company and the Agent wish to amend the title, introductory paragraph and Sections 2(a), 3(q), 7(a) and 9 of the Agreement to remove

the limit on the number of shares of the Company’s common stock that may be sold pursuant to the Agreement and to make necessary

updates to references throughout the Agreement to the Company’s legal counsel.

NOW,

THEREFORE, in consideration of the mutual agreements contained herein and other good and valuable consideration, the receipt and sufficiency

of which are hereby acknowledged, and intending to be legally bound hereby, the Company and the Agent hereby agree as follows:

Title of the Agreement. The title of the Agreement is hereby amended and restated in its entirety as follows:

AIM

ImmunoTech Inc.

Equity

Distribution Agreement

Amendment to the Introductory Paragraph of the Agreement. The introductory paragraph of the Agreement is hereby amended and restated

in its entirety as follows:

“AIM

ImmunoTech Inc., a Delaware corporation (the “Company”), proposes to issue and sell through Maxim Group LLC

(the “Agent”), as sales agent, shares of common stock, par value $0.001 per share (“Common Stock”),

of the Company (the “Shares”) on terms set forth herein. The Shares consist entirely of authorized but unissued

shares of Common Stock to be issued and sold by the Company.”

Amendment to “Purchase, Sale and Delivery of Shares.” Sections 2(a) and 2(a)(i) of the Agreement is hereby

amended and restated in its entirety as follows:

(a)

At the Market Sales. On the basis of the representations, warranties and agreements herein the Company agrees that, from time

to time after the effective date of the Registration Statement on the terms and subject to the conditions set forth herein, it may issue

and sell through the Agent, acting as sales agent, Shares; provided, however, that in no event shall the Company issue or sell through

the Agent such number of Shares that (a) exceeds the number or dollar amount of shares of Common Stock registered on the Registration

Statement pursuant to which the Offering is being made, (b) exceeds the number of authorized but unissued shares of Common Stock under

the Company’s Amended and Restated Certificate of Incorporation, as amended or (c) would cause the Company or the Offering to not

satisfy the eligibility and transaction requirements for use of Form S-3 (including, if then applicable, General Instruction I.B.6 of

Form S-3) (the lesser of (a), (b) and (c), the “Maximum Amount”). Notwithstanding anything to the contrary

contained herein, the parties hereto agree that compliance with the limitations set forth in this Section 2(a) on the number and aggregate

sales price of Shares issued and sold under this Agreement shall be the sole responsibility of the Company and the Agent shall have no

obligation in connection with such compliance. Notwithstanding the foregoing, the Company agrees that it will provide the Agent with

written notice of the Maximum Amount available for sale of the Shares no less than one (1) Business Day prior to the date on which it

makes the initial sale of Shares under this Agreement. “Business Day”, as used herein, shall mean any day other

than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized or required by law to remain closed;

provided that banks shall not be deemed to be authorized or obligated to be closed due to a “shelter in place,” “non-essential

employee” or similar closure of physical branch locations at the direction of any governmental authority if such banks’ electronic

funds transfer systems (including for wire transfers) are open for use by customers on such day.

(i)

For purposes of selling the Shares through the Agent, the Company hereby appoints the Agent as agent of the Company for the purpose of

soliciting purchases of the Shares from the Company pursuant to this Agreement and the Agent agrees to use its commercially reasonable

efforts to sell the Shares on the terms and subject to the conditions stated herein.

Amendment to “Covenant.” Section 3(q) of the Agreement is hereby amended restated in its entirety as follows:

(q)

(1) On the date hereof, the Company shall cause (A) Thompson Hine LLP, counsel for the Company, to furnish to the Agent its written opinion

and negative assurance letter, in form and substance reasonably acceptable to Agent’s counsel and (B) Studebaker & Brackett

PC, intellectual property legal counsel to the Company, to furnish to the Agent its written opinion, in form and substance reasonably

acceptable to Agent’s counsel, and the Agent shall cause (C) Ellenoff Grossman & Schole LLP, as counsel for the Agent to furnish

to the Agent its negative assurance letter.

(2)

On each date that the Company (i) amends or supplements the Registration Statement after the effective date of the Registration Statement

or the Prospectus (other than by means of incorporation by reference); (ii) files an annual report on Form 10-K under the Exchange Act;

(iii) files its quarterly reports on Form 10-Q under the Exchange Act; (iv) files a report on Form 8-K under the Exchange Act containing

amended financial information (other than an earnings release, to “furnish” information pursuant to Items 2.02 or 7.01 of

Form 8-K, unless the Agent reasonably determines that the information in such Form 8-K is material); or (v) otherwise after each reasonable

request by Agent (each of such date referred to herein as a “Bringdown Date”), the Company shall cause (X) Thompson Hine

LLP, counsel for the Company, to furnish to the Agent its opinion and negative assurance letter, in form and substance reasonably acceptable

to Agent’s counsel, and (Y) Studebaker & Brackett PC, intellectual property legal counsel to the Company, to furnish to the

Agent its written opinion, in form and substance reasonably acceptable to Agent’s counsel, and the Agent shall cause (Z) Ellenoff

Grossman & Schole LLP, as counsel for the Agent to furnish to the Agent its negative assurance letter, each dated as of a date within

ten (10) days after the applicable Bringdown Date, addressed to the Agent and modified as necessary to relate to the Registration Statement

and the Prospectus as amended and supplemented to the time of delivery of such opinions. With respect to this Section 3(q)(2), in lieu

of delivering such opinions or letters for Bringdown Dates subsequent to the date of effectiveness of the Registration Statement, such

counsel may furnish agent with a letter (a “Reliance Letter”) to the effect that Agent may rely upon a prior opinion or letter

delivered under Section 3(q)(1) or this Section 3(q)(2) to the same extent as if it were dated the date of such letter (except that statements

in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended or supplemented as of the

date of Reliance Letter). Provided, however, the requirement to provide opinions and letters under this Section 3(q)(2) is hereby waived

for any Bringdown Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to

occur of the date the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing,

if the Company subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide

Agent with opinions and letters under this Section 3(q)(2), then before the Company delivers the Transaction Notice or Agent sells any

Shares, the Company shall cause each of Thompson Hine LLP to furnish to the Agent a written opinion and negative assurance letter, and

Studebaker & Brackett PC to furnish to the agent its written opinion, and the Agent shall cause Ellenoff Grossman & Schole LLP

to furnish to the Agent its negative assurance letter, dated the date of the Transaction Notice.

Amendment to “Termination of this Agreement.” Section 7 of the Agreement is hereby amended and restated in

its entirety as follows:

“7.

Termination of this Agreement. The term of this Agreement shall begin on the date hereof, and shall continue until termination

by either the Agent and the Company upon the provision of fifteen (15) days written notice. Any such termination by mutual agreement

shall in all cases be deemed to provide that Section 3(g), Section 5 and Section 6 shall remain in full force and effect. Notwithstanding

the foregoing, the Agent shall have the right, in its sole discretion, to terminate this Agreement if at any time from the date of this

Agreement to the effectiveness of the Registration Statement, the Agent is not fully satisfied, in its sole discretion, with the results

of its and its representatives’ review of the Company and the Company’s business.”

Amendment to “Notice.” Section 9 of the Agreement is hereby amended and restated in its entirety as follows:

“9.

Notices. Except as otherwise provided herein, all communications under this Agreement shall be in writing and, if to the

Agent, shall be mailed, delivered or telecopied to Maxim Group LLC, 300 Park Avenue, 16th Floor, New York, New York 10022, Attention:

Clifford A. Teller and James Siegel, with a required copy (which shall not constitute notice) to Ellenoff Grossman & Schole LLP,

counsel for the Agent, at 1345 Avenue of the Americas, New York, New York 10105 Attention: Matt Bernstein, Esq. Notices to the Company

shall be given to it at 2117 SW Highway 484, Ocala FL 34473 Attention: Chief Executive Officer, with required copies (which shall not

constitute notice) to Thompson Hine LLP, 300 Madison Avenue, 27th Floor, New York, New York 10017, Attention: Faith L. Charles. Any party

to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address for

such purpose.”

No Further Amendment. Except as amended by this Amendment, the Agreement remains

unaltered and shall remain in full force and effect.

Jurisdiction. All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be determined

in accordance with the provisions of the Agreement.

Counterparts. This Amendment may be executed in any number of counterparts, each of which will be deemed an original and all of

which together will constitute one and the same instrument. Signatures delivered by facsimile, electronic mail (including as a PDF file)

or other transmission method shall be deemed to be original signatures, shall be valid and binding, and, upon delivery, shall constitute

due execution of this Amendment.

[Signature

page follows]

WITNESS WHEREOF, each of the Company and the Agent has caused this Amendment to be executed and delivered by its officer thereunto duly

authorized as of the date first above indicated.

COMPANY

AIM IMMUNOTECH INC.

By:

/s/

Thomas K. Equels

Name:

Thomas K. Equels

Title:

Chief Executive Officer

AGENT

MAXIM GROUP LLC

By:

/s/

Ritesh Veera

Name:

Ritesh Veera

Title:

Co-Head of Investment

Banking | Executive Managing Director

EX-5.1

Filename: ex5-1.htm · Sequence: 3

Exhibit

5.1

April

10, 2026

AIM

ImmunoTech Inc.

2117

SW Highway 484

Ocala,

FL 34473

Re:

AIM ImmunoTech Inc. Common Stock

Ladies

and Gentlemen:

have acted as counsel to AIM ImmunoTech Inc., a Delaware corporation (the “Company”), with respect to certain

matters in connection with the offering by the Company of $3,409,174 of shares of the Company’s common stock, par value

$0.001 per share (the “Shares”), pursuant to the Registration Statement on Form S-3 (File No. 333-286319) (the

“Registration Statement”), filed with the Securities and Exchange Commission (the “Commission”)

under the Securities Act of 1933, as amended (the “Act”), the related prospectus dated July 3, 2025 included

within the Registration Statement (the “Base Prospectus”), the prospectus supplement dated October 30, 2025,

and the amendment to the prospectus supplement dated April 10, 2026, filed with the Commission pursuant to Rule 424(b) promulgated under

the Act (together with the Base Prospectus, the “Prospectus”). The Shares are to be sold by the Company in

accordance with the Equity Distribution Agreement dated April 1, 2025, as amended on April 10, 2026, by and between the Company and Maxim

Group LLC (the “EDA”), as described in the Prospectus.

rendering this opinion, we have examined and are familiar with the following:

The

Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws of the Company, as amended and restated through

the date hereof (the “Certificate of Incorporation” and “Bylaws”, respectively).

The

Registration Statement.

The

Prospectus.

Such

other records, instruments, documents, and certificates as we have deemed advisable in order to render such opinion.

such examination, we have assumed:

The

genuineness of all signatures.

The

legal capacity of all natural persons.

The

authenticity of all documents submitted to us as originals.

The

conformity to original documents of all documents submitted to us as copies.

AIM

ImmunoTech Inc.

April

10, 2026

Page

Based

upon and subject to the foregoing and such other investigation as we have deemed necessary and subject to the qualifications set forth

below, we are of the opinion that the Shares, when issued by the Company out of the Company’s duly authorized common stock and

issued and delivered by the Company against payment therefor as contemplated by and in accordance with the terms of the EDA, on terms

approved by the Board of Directors of the Company, or a duly authorized committee thereof, will be duly and validly issued, fully paid

and nonassessable.

Our

opinions expressed above are limited to the General Corporation Laws of the State of Delaware and laws of the State of New York, in each

case as currently in effect (collectively, “Applicable Law”), and we express no opinion as to the effect on

the matters covered by this letter of the laws of any other jurisdiction.

have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed

by us to be responsible.

Please

note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters.

This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to

advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or

opinions set forth herein.

hereby consent to the filing of this opinion as an exhibit to a Current Report on Form 8-K in accordance with the requirements of Item

601(b)(5) of Regulation S-K under the Act. In giving such consent, we do not hereby admit that we are in the category of persons whose

consent is required under Section 7 of the Act or the rules and regulations of the Commission.

Very

truly yours,

/s/

Thompson Hine LLP

Thompson

Hine LLP

GRAPHIC

Filename: ex5-1_001.jpg · Sequence: 4

Binary file (22438 bytes)

Download ex5-1_001.jpg

GRAPHIC

Filename: ex5-1_002.jpg · Sequence: 5

Binary file (21814 bytes)

Download ex5-1_002.jpg

GRAPHIC

Filename: ex5-1_003.jpg · Sequence: 6

Binary file (14450 bytes)

Download ex5-1_003.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 11

v3.26.1

Cover

Apr. 10, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 10, 2026

Entity File Number

001-27072

Entity Registrant Name

AIM

IMMUNOTECH INC.

Entity Central Index Key

0000946644

Entity Tax Identification Number

52-0845822

Entity Incorporation, State or Country Code

Entity Address, Address Line One

2117

SW Highway 484

Entity Address, City or Town

Ocala

Entity Address, State or Province

Entity Address, Postal Zip Code

34473

City Area Code

(352)

Local Phone Number

448-7797

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

Stock, par value $0.001 per share

Trading Symbol

AIM

Security Exchange Name

NYSEAMER

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration